Working… Menu

QUILT-3.018: Neukoplast™ (NK-92) for the Treatment of Refractory or Relapsed Acute Myeloid Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00900809
Recruitment Status : Completed
First Posted : May 13, 2009
Last Update Posted : June 13, 2018
Information provided by (Responsible Party):
ImmunityBio, Inc.

Brief Summary:

NK cells from patients with malignant diseases are often functionally impaired. Their function cannot be fully restored through ex vivo expansion and cytokine activation. In addition, the in vivo administration of cytokines not only expands NK cells but expands polyclonal T cells with no tumor specificity and no known effects.

The utilization of Neukoplast™, as a form of adoptive immunotherapy, offers several advantages. Neukoplast™ represents a uniform cell population with a well-characterized immunophenotype, confirmed strong anti-tumor activity and are easy to grow and expand in culture, so that they can be made available in large numbers for therapeutic delivery.

Condition or disease Intervention/treatment Phase
Acute Myeloid Leukemia Biological: Neukoplast™ (NK-92) Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 7 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Study of Adoptive Immunotherapy Using the Natural Killer Cell Line, Neukoplast™(NK-92), for the Treatment of Refractory or Relapsed Acute Myeloid Leukemia
Actual Study Start Date : May 12, 2014
Actual Primary Completion Date : June 2, 2015
Actual Study Completion Date : June 2, 2015

Arm Intervention/treatment
Experimental: Neukoplast™ (NK-92)
Neukoplast™ will be infused in three doses.1 x 10e9 cells/m2 dose, 3 x 10e9 cells/m2 dose, 5 x 10e9 cells/m2 dose.
Biological: Neukoplast™ (NK-92)
The Neukoplast™ (NK-92) cells will be administered intravenously over 60 minutes. The starting dose of Neukoplast™ (NK-92) cells will be 1 x 10e9 ZRx-101 cells/m2 (The 3 dose levels are: 1 x 10e9 cells/m2, 3 x 10e9 cells/m2 and 5 x 10e9 cells/m2). The second infusion will only be administered after 24 hours if no unacceptable or dose limiting toxicities side effects due to the infusion of Neukoplast™ were encountered after the first infusion.

Primary Outcome Measures :
  1. Determine the safety / maximum tolerated dose of Neukoplast™ (NK-92 cell line for clinical use) in patients with refractory or relapsed acute myeloid leukemia [ Time Frame: 2016 ]

Secondary Outcome Measures :
  1. Evaluate the therapeutic efficacy of Neukoplast™ in patients with refractory or relapsed acute myeloid leukemia [ Time Frame: 2016 ]
  2. Determine the Neukoplast™ cell phenotype and cytotoxic activity at different time intervals after the Neukoplast™ cell infusion [ Time Frame: 2016 ]
  3. Determine the presence of Neukoplast™ in the bone marrow [ Time Frame: 2016 ]
  4. Determine the effects of Neukoplast™ on the host immune system, using flow cytometry and the LUMINEX multianalytic profiling system, at different time intervals after the Neukoplast™ infusion. [ Time Frame: 2016 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with refractory/relapse acute myeloid leukemia. Patients must not have received radiotherapy, chemotherapy (with the exception of hydroxyurea which must be discontinued 72 hours prior to therapy) or biological therapy within the preceding 2 weeks of the planned first Neukoplast™ cell infusion and must have recovered from any adverse events due to prior administered agents
  • Assessable disease as measured by laboratory and bone marrow examinations
  • Age: Eighteen years or older
  • Performance status: ECOG ≤ 2 (Appendix A)
  • Serum creatinine < 2 X upper limit of normal
  • Aspartate aminotransferase (AST) < 5 X upper limit of normal
  • Alanine aminotransferase (ALT) < 5 X upper limit of normal
  • Total bilirubin < 3X upper limit of normal
  • Activated partial thromboplastin time (PTT) < 2.5 X upper limit of normal
  • Patients must have left ventricular ejection fraction (LVEF) ≥45 %
  • Females of child-bearing potential must have a negative pregnancy test and all subjects must agree to use an effective method of contraception for up to two weeks after the last infusion of Neukoplast™
  • Ability to give informed consent
  • Life expectancy of greater than 3 months

Note: as many of eligible patients will be pancytopenic secondary to their disease or prior therapies hematologic abnormalities will not be used as a criteria for entry or exclusion.

Exclusion Criteria:

  • Patients with acute promyelocytic leukemia
  • Symptomatic central nervous system (CNS) involvement
  • History of congestive heart failure
  • Evidence of severe or uncontrolled systemic diseases (e.g., unstable or uncompensated respiratory, hepatic, renal, or cardiac disease).
  • Uncontrolled, life-threatening infection that is not responding to antimicrobial therapy
  • ECOG performance status >2 (Appendix A)
  • Hepatitis B or C or HIV positive serology
  • History of psychiatric disorder which may compromise compliance with the protocol or which does not allow for appropriate informed consent
  • Patient may not be receiving any other investigational agents
  • Patient is receiving systemic anticoagulation (e.g., warfarin, intravenous heparin. Low dose prophylactic anticoagulation is allowed )
  • Patient undergone autologous or allogeneic stem cell transplantation
  • Concurrent malignancy of solid tumors. Exception: Subjects who have been disease-free for 5 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible. Subjects with second malignancies that are indolent or definitively treated may be enrolled.
  • Pregnant or lactating female.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00900809

Layout table for location information
United States, Pennsylvania
UPMC Cancer Center - Hillman Cancer Center
Pittsburgh, Pennsylvania, United States, 15232
Sponsors and Collaborators
ImmunityBio, Inc.
Layout table for investigator information
Principal Investigator: Michael Boyiadzis, MD University of Pittsburgh Medical Center
Layout table for additonal information
Responsible Party: ImmunityBio, Inc. Identifier: NCT00900809    
Other Study ID Numbers: QUILT-3.018
First Posted: May 13, 2009    Key Record Dates
Last Update Posted: June 13, 2018
Last Verified: March 2017
Keywords provided by ImmunityBio, Inc.:
Acute Myeloid Leukemia
Refractory or Relapsed Acute Myeloid Leukemia
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type